Format

Send to

Choose Destination
AIDS. 2007 Sep 12;21(14):1977-80.

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

Author information

1
University of Nantes, Nantes, France.

Erratum in

  • AIDS. 2008 Aug 20;22(13):i.

Abstract

In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations. Transaminase elevation rates (6.5%) and clinical hepatic event rates (5.9 events/100 person exposure years) were lower in the tipranavir/ritonavir with enfuvirtide group than in the tipranavir/ritonavir without enfuvirtide group. Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity.

PMID:
17721109
DOI:
10.1097/QAD.0b013e3282ef8600
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for Archivio Istituzionale della Ricerca Unimi
Loading ...
Support Center